Overview of Revatio
| Property | Description |
|---|---|
| Active ingredient | Sildenafil citrate |
| Forms | Oral tablet, Oral suspension, Intravenous (IV) solution |
| Pharmacological class | Phosphodiesterase type 5 (PDE5) inhibitor, Vasodilator |
| Common purpose | Managing high pressure in the pulmonary arteries |
| Origin | Synthetic compound |
What is Revatio and How is it Classified?
Revatio is a specific, synthetic medication available only by prescription, primarily known for its active ingredient, Sildenafil citrate. It is classified pharmacologically as a Phosphodiesterase type 5 (PDE5) inhibitor, placing it within a class of drugs that function as targeted vasodilators. Pharmacological studies support the compound's focused efficacy in the circulatory system. This compound has been approved for its general purpose of managing symptoms associated with severe hypertension in the arteries of the lungs. This distinct focus on pulmonary circulation, often differentiating it from other products containing Sildenafil, ensures that the treatment is aligned with patient populations needing specialized cardiac and pulmonary support.
Composition and Available Pharmaceutical Forms
The preparation known as Revatio is a single active ingredient product, containing only Sildenafil citrate as the therapeutic compound. This medicine is supplied in three distinct dosage form(s) to ensure adaptability across patient care settings: the standard oral tablet, an oral suspension for flexible dosing, and a sterile intravenous (IV) solution. The availability of these forms ensures that the administration route, whether oral or intravenous, can be tailored to the individual patient’s clinical status and ability to swallow, including use in pediatric patients. The oral tablet and suspension rely on solid or liquid excipients for stability and absorption, while the IV solution utilizes an aqueous base for direct delivery into the bloodstream, a critical differentiating factor for hospital use.
The Core Function: Mechanism Principle and General Benefit
The core function of the active ingredient Sildenafil is rooted in the principle of selective enzyme inhibition, which leads to pulmonary vasodilation. By preventing the breakdown action of the PDE5 enzyme, the drug stabilizes crucial signaling molecules required for the relaxation and subsequent widening of vascular smooth muscle within the lungs. This fundamental mechanism is clinically recognized for its ability to reduce the resistance and pressure within the pulmonary arteries. The overall outcome of this targeted action is a decrease in the heart's workload and an optimization of blood flow through the lungs, supporting the efficient circulation of oxygenated blood throughout the body, a benefit crucial in scenarios where pulmonary pressure is compromised.
Regulatory References
